<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10437R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Molecular Biology</subject><subject>Biochemistry/Cell Signaling and Trafficking Structures</subject><subject>Molecular Biology/Transcription Initiation and Activation</subject></subj-group></article-categories><title-group><article-title>Ligand Modulated Antagonism of PPAR&#x003b3; by Genomic and Non-Genomic Actions of PPAR&#x003b4;</article-title><alt-title alt-title-type="running-head">PPAR&#x003b4; Mediated Repression</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gustafsson</surname><given-names>Mattias C. U.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knight</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="author-notes" rid="fn2"><sup>&#x000a4;b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>Colin N. A.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><addr-line>Biomedical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Delprato</surname><given-names>Anna Maria</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Centre National de la Recherche Scientifique, France</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>Mattias.Gustafsson@med.lu.se</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MCUG DK CNP. Performed the experiments: MCUG DK. Analyzed the data: MCUG DK CNP. Wrote the paper: MCUG CNP.</p></fn><fn id="fn1" fn-type="current-aff"><label>&#x000a4;a</label><p>Current address: Department of Laboratory Medicine, Division of Medical Microbiology, Lund University, Lund, Sweden</p></fn><fn id="fn2" fn-type="current-aff"><label>&#x000a4;b</label><p>Current address: Malaghan Institute of Medical Research, Wellington, New Zealand</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>9</month><year>2009</year></pub-date><volume>4</volume><issue>9</issue><elocation-id>e7046</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Gustafsson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Members of the Peroxisome Proliferator Activated Receptor, PPAR, subfamily of nuclear receptors display complex opposing and overlapping functions and a wide range of pharmacological and molecular genetic tools have been used to dissect their specific functions. Non-agonist bound PPAR&#x003b4; has been shown to repress PPAR Response Element, PPRE, signalling and several lines of evidence point to the importance of PPAR&#x003b4; repressive actions in both cardiovascular and cancer biology.</p></sec><sec><title>Methodology/Principal Findings</title><p>In this report we have employed transient transfections and luciferase reporter gene technology to study the repressing effects of PPAR&#x003b4; and two derivatives thereof. We demonstrate for the first time that the classical dominant negative deletion of the Activation Function 2, AF2, domain of PPAR&#x003b4; show enhanced repression of PPRE signalling in the presence of a PPAR&#x003b4; agonist. We propose that the mechanism for the phenomenon is increased RXR heterodimerisation and DNA binding upon ligand binding concomitant with transcriptional co-repressor binding. We also demonstrated ligand-dependent dominant negative action of a DNA non-binding derivative of PPAR&#x003b4; on PPAR&#x003b3;1 signalling. This activity was abolished upon over-expression of RXR&#x003b1; suggesting a role for PPAR/cofactor competition in the absence of DNA binding.</p></sec><sec><title>Conclusions/Significance</title><p>These findings are important in understanding the wide spectrum of molecular interactions in which PPAR&#x003b4; and PPAR&#x003b3; have opposing biological roles and suggest novel paradigms for the design of different functional classes of nuclear receptor antagonist drugs.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The peroxisome proliferator-activated receptors (PPARs) &#x003b1;, &#x003b4; and &#x003b3; belong to the nuclear receptor family of transcriptional regulators. They function as obligate heterodimers with the retinoid X receptors, RXRs, and signal from PPAR response elements (PPREs) upon binding PPAR- and/or RXR agonists. The PPAR ligands consist of naturally occurring fatty acids and fatty acid derivatives as well as a range of synthetic drugs <xref ref-type="bibr" rid="pone.0007046-Desvergne1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Staels1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Willson1">&#x0005b;3&#x0005d;</xref>.</p><p>PPAR&#x003b1; is involved in the control of catabolic fatty acid metabolism such as peroxisomal &#x003b2;-oxidation and mitochondrial &#x003b2;-and &#x003c9;-oxidation of fatty acids and is most prevalent in metabolically active tissues such as liver. PPAR&#x003b1; is activated by the blood lipid lowering fibrate drugs. These acts as peroxisome proliferators in mice and rats but no adverse effects have been detected in human livers <xref ref-type="bibr" rid="pone.0007046-Desvergne1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Tachibana1">&#x0005b;4&#x0005d;</xref>.</p><p>PPAR&#x003b3; is involved in fatty acid and glucose homeostasis and is required for adipocyte differentiation and for placental development. Activation of PPAR&#x003b3; also seems to act anti-inflammatory and to hinder proliferation or cause apoptosis in cancer cells. The insulin sensitizing thiazolidinedione drugs, which are high affinity PPAR&#x003b3; agonists, are used to treat type 2 diabetes and experimentally to treat cancer <xref ref-type="bibr" rid="pone.0007046-Tontonoz1">&#x0005b;5&#x0005d;</xref>.</p><p>PPAR&#x003b4; is widely expressed and the most prevalent PPAR in several tissues both in the adult organism and during development <xref ref-type="bibr" rid="pone.0007046-Abbott1">&#x0005b;6&#x0005d;</xref>. It is also the least known in terms of biological function, although recent reports would suggest that it might have a role similar to PPAR&#x003b1; in tissues other than liver. PPAR&#x003b4; has also been shown to be involved in placental implantation, wound healing, and carcinogenesis <xref ref-type="bibr" rid="pone.0007046-Tachibana1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Desvergne2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Seedorf1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Takahashi1">&#x0005b;9&#x0005d;</xref>. No PPAR&#x003b4; ligands are currently used as such in treatment of disease, although studies on human subjects for the use of a PPAR&#x003b4; agonist in the treatment of metabolic syndrome have been reported <xref ref-type="bibr" rid="pone.0007046-Riserus1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Sprecher1">&#x0005b;11&#x0005d;</xref>.</p><p>Recently, it was shown that non-liganded PPAR&#x003b4; attracts transcriptional co-repressors when bound to DNA more effectively than PPAR&#x003b1; and &#x003b3;. Due to its widespread distribution it was suggested that PPAR&#x003b4; acts as a PPRE gateway receptor <xref ref-type="bibr" rid="pone.0007046-Krogsdam1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Shi1">&#x0005b;13&#x0005d;</xref>. Given the, sometimes conflicting, results on PPAR&#x003b4; biology obtained using various pharmacological and molecular genetic tools we set out to study the ligand modulated antagonism of PPAR&#x003b3;1 by genomic and non-genomic actions of PPAR&#x003b4;. We found in accordance with <xref ref-type="bibr" rid="pone.0007046-Shi1">&#x0005b;13&#x0005d;</xref> that non-liganded PPAR&#x003b4; represses PPAR&#x003b1; and &#x003b3;. In line with this the PPAR&#x003b4; derivative PPAR&#x003b4;&#x00394;AF2, lacking helix 12 (or activation function 2, AF2), acts dominant negatively on PPAR&#x003b1;, &#x003b3;1 and &#x003b4; signalling. Furthermore, we found that PPAR&#x003b4;&#x00394;AF2 possess ligand enhanced dominant negative activity on PPRE signalling. In contrast to Shi et al. <xref ref-type="bibr" rid="pone.0007046-Shi1">&#x0005b;13&#x0005d;</xref> who reported that a non-DNA binding PPAR&#x003b4; derivative didn't exert any dominant negative effects, we found that non-DNA bound PPAR&#x003b4; ligand-binding domain (LBD) exerts ligand-dependent dominant negative activity on PPAR&#x003b3;1 signalling. Since PPAR&#x003b4; and &#x003b3; co-exist in a range of tissues and in many cases have opposite biological effects we propose that the phenomena discovered might have important implications for PPAR experimental designs, PPAR biology in general and possibly drug design.</p></sec><sec id="s2"><title>Results and Discussion</title><sec id="s2a"><title>Agonist non-bound PPAR&#x003b4; is a repressor of PPAR&#x003b3;1 dependent PPRE signalling, but not vice versa</title><p>Due to its widespread tissue distribution and the fact that it interacts more efficiently on DNA with nuclear receptor co-repressors than the other PPAR isoforms it was proposed, as well as demonstrated <italic>in vitro</italic>, that PPAR&#x003b4; functions as a PPRE gateway receptor <xref ref-type="bibr" rid="pone.0007046-Krogsdam1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Shi1">&#x0005b;13&#x0005d;</xref>. We confirmed this phenomenon for PPAR&#x003b4; and &#x003b3;1 signalling using transient transfection of COS-1 cells with plasmids encoding these PPAR isoforms and a promiscuous (transcriptionally transactivated by all three PPAR isoforms, data not shown for PPAR&#x003b1;), PPRE luciferase reporter gene construct (pLFABPluc). We found that the presence of unliganded PPAR&#x003b3;1 did not affect PPAR&#x003b4; signalling (<xref ref-type="fig" rid="pone-0007046-g001">Figure 1A</xref>) whereas unliganded PPAR&#x003b4; significantly (P&#x0003c;0.001) repressed the PPAR&#x003b3;1 dependent signalling from pLFABPluc (<xref ref-type="fig" rid="pone-0007046-g001">Figure 1B</xref>).</p><fig id="pone-0007046-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007046.g001</object-id><label>Figure 1</label><caption><title>The effect of (A) non-liganded PPAR&#x003b3;1 on PPAR&#x003b4; signalling and of (B) non-liganded PPAR&#x003b4; on PPAR&#x003b3;1 signalling.</title><p>COS-1 cells were transiently transfected with (per well in six-well plates) 50 ng (A) pCLDN-hPPAR&#x003b4; or (B) pCDLN-hPPAR&#x003b3;1 and 250 ng (A) pCLDN or pCLDN-hPPAR&#x003b3;1 and (B) pCLDN or pCLDN-hPPAR&#x003b4;, respectively.</p></caption><graphic xlink:href="pone.0007046.g001"/></fig></sec><sec id="s2b"><title>Ligand-enhanced dominant negative action of PPAR&#x003b4;&#x00394;AF2</title><p>Helix 12 modifications (both designed and for PPAR&#x003b3;, found in human patients as mutations) have been shown to render PPARs dominant negative due to their inability to recruit co-activators while retaining the ability to bind co-repressors <xref ref-type="bibr" rid="pone.0007046-Barroso1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Hatae1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Michalik1">&#x0005b;16&#x0005d;</xref>. Given the superior repressing properties of PPAR&#x003b4;, modification of helix 12 should render it a relatively effective ligand independent repressor of PPRE signalling. We have previously employed a PPAR&#x003b4; derivative lacking the C-terminal 11 amino acid residues, PPAR&#x003b4;&#x00394;AF2, as a tool for studying PPRE signalling <xref ref-type="bibr" rid="pone.0007046-TargettAdams1">&#x0005b;17&#x0005d;</xref>. In order to further characterize the properties of this construct we conducted a range of transient transfection experiments. PPAR&#x003b4;&#x00394;AF2 was found to act in a dominant negative fashion on PPAR&#x003b1;, &#x003b3;1 and &#x003b4; signalling (<xref ref-type="fig" rid="pone-0007046-g002">Figure 2A &#x00026; B</xref>, respectively, P&#x0003c;0.001, data not shown for PPAR&#x003b1;), thus confirming and extending our previous observations.</p><fig id="pone-0007046-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007046.g002</object-id><label>Figure 2</label><caption><title>PPAR&#x003b4;&#x00394;AF2 represses (A) PPAR&#x003b4; and (B) PPAR&#x003b3;1 signalling. (C) PPAR&#x003b4;&#x00394;AF2 represses TK-promoter activity in a ligand-enhanced fashion.</title><p>COS-1 cells were transiently transfected with (per well in six-well plates) (A) 50 ng pCLDN-hPPAR&#x003b4; or (B) pCDLN-hPPAR&#x003b3;1 and 250 ng pCLDN or pCLDN-hPPAR&#x003b4;&#x00394;AF2. (C) and (D) T47D cells were transfected with (per well in a six-well plate) 500 ng pCLDN, pCLDN-hPPAR&#x003b4;&#x00394;AF2 or pCLDN-hPPAR&#x003b4;. (D) is identical to (C) except for the two additional bars representing over-expression of PPAR&#x003b4; with and without CF.</p></caption><graphic xlink:href="pone.0007046.g002"/></fig><p>Upon agonist binding PPARs undergo a conformational change leading to increased RXR heterodimerisation and shedding of transcriptional co-repressors with the subsequent recruitment of transcriptional co-activators <xref ref-type="bibr" rid="pone.0007046-Willson1">&#x0005b;3&#x0005d;</xref>. The increased PPAR-RXR heterodimerisation leads to an increased affinity for PPREs <xref ref-type="bibr" rid="pone.0007046-Forman1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-He1">&#x0005b;19&#x0005d;</xref>. This would in the case of PPAR&#x003b4;&#x00394;AF2 lead to increased occupancy of the PPREs concomitant with recruitment of transcriptional co-repressors and thus further reduced PPRE signalling. We thus investigated the effect of a PPAR&#x003b4; agonist on the dominant negative properties of PPAR&#x003b4;&#x00394;AF2. Because of the relatively high endogenous PPRE signalling in the COS-1 cells we employed T47D cells grown in RPMI 1640 medium supplemented with 5&#x00025; dextran charcoal-stripped serum for this experiment. The effect of over-expressing and transactivating PPAR&#x003b4; in T47D cells is shown in <xref ref-type="fig" rid="pone-0007046-g002">Figure 2D</xref>. We could detect a small but significant (P&#x0003c;0.001) PPAR&#x003b4; (CF dependent) activity in cells with no added PPAR&#x003b4; expression vector (<xref ref-type="fig" rid="pone-0007046-g002">Figure 2C</xref>). We could also see a small but significant (P&#x0003c;0.01) effect of introducing PPAR&#x003b4;&#x00394;AF2 on non-CF dependent transcription of the luciferase gene in pLFABPluc (<xref ref-type="fig" rid="pone-0007046-g002">Figure 2C</xref>). The dominant negative effect of introducing PPAR&#x003b4;&#x00394;AF2 into the system was further enhanced by the addition of CF (P&#x0003c;0.001). This indicates that for PPAR&#x003b4;&#x00394;AF2 CF acts as an inverse agonist that enhances the dominant negative effect, a novel concept for type II nuclear receptors. The concept was discussed and investigated for the only PPAR&#x003b4; antagonist described to date, GSK0660. GSK0660 did not, however, increase occupancy of PPAR&#x003b4; or transcriptional co-repressors to chromatin PPREs <xref ref-type="bibr" rid="pone.0007046-Shearer1">&#x0005b;20&#x0005d;</xref>.</p></sec><sec id="s2c"><title>The PPAR&#x003b4; ligand-binding domain is a repressor of PPRE dependent PPAR&#x003b3;1 signalling in the presence of a PPAR&#x003b4; agonist</title><p>Since the PPARs act as RXR heterodimers it would be conceivable that RXR competition could occur among the PPAR isoforms. In fact, ligand dependent RXR competition has been described for PPAR&#x003b1; and liver X receptor (LXR) <xref ref-type="bibr" rid="pone.0007046-Ide1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Yoshikawa1">&#x0005b;22&#x0005d;</xref>, PPAR&#x003b2;/&#x003b4; and LXR&#x003b1; <xref ref-type="bibr" rid="pone.0007046-Matsusue1">&#x0005b;23&#x0005d;</xref>, PPAR&#x003b1; and thyroid hormone receptor (TR) <xref ref-type="bibr" rid="pone.0007046-Chu1">&#x0005b;24&#x0005d;</xref> as well as PPAR&#x003b3; and TR&#x003b1;1 and &#x003b2; mutants <xref ref-type="bibr" rid="pone.0007046-Ying1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Araki1">&#x0005b;26&#x0005d;</xref>. Agonist-bound wild-type PPAR&#x003b4; and &#x003b3; activate transcription when bound to PPREs. Thus, in order to study the PPRE independent effects of PPAR&#x003b4; and &#x003b3; we needed a non-DNA binding derivative with a functional ligand binding and activating domain. We generated an expression plasmid for the PPAR&#x003b4; LBD, pCLDN-&#x003b4;LBD, and tested it for the desired properties in a mammalian two-hybrid assay. Co-expression of the GAL4-RXR&#x003b1; fusion protein and the PPAR&#x003b4; LBD led to CF induced upstream activating sequence (UAS) dependent transcriptional transactivation, strongly indicating that the PPAR&#x003b4; LBD is functional with respect to RXR heterodimerisation and transcriptional co-activator recruitment (<xref ref-type="fig" rid="pone-0007046-g003">Figure 3A</xref>, P&#x0003c;0.001).</p><fig id="pone-0007046-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007046.g003</object-id><label>Figure 3</label><caption><title>(A) The PPAR&#x003b4; LBD is functional with respect to transcriptional transactivation and RXR heterodimerisation and (B), (C) and (D) possess ligand-dependent dominant negative behaviour.</title><p>(A) COS-1 cells were transfected with 500 ng pCMVgRXR and 500 ng pCLDN or pCLDN-&#x003b4;LBD. (B), (C) and (D) COS-1 cells were transiently transfected with: (B) 500 ng pJ3Nuc (hPPAR&#x003b4; expression plasmid) and 0 to 500 ng pCLDN or pCLDN-&#x003b4;LBD; (C) 50 ng pCLDN-hPPAR&#x003b3;1 and 0 to 500 ng pCLDN or pCLDN-&#x003b4;LBD; (D) 50 ng pCLDN-hPPAR&#x003b3;1 and 500 ng pCLDN-&#x003b4;LBD.</p></caption><graphic xlink:href="pone.0007046.g003"/></fig><p>Subsequent to the functional validation of the PPAR&#x003b4; LBD we investigated whether it had a dominant negative effect on PPAR&#x003b4; and &#x003b3;1 signalling. We found that PPAR&#x003b4; but not PPAR&#x003b3;1 signalling was abolished by co-expression of the PPAR&#x003b4; LBD (<xref ref-type="fig" rid="pone-0007046-g003">Figures 3B</xref> (P&#x0003c;0.001) and C, respectively). One important difference between the experiments in <xref ref-type="fig" rid="pone-0007046-g003">Figures 3B and C</xref> is the absence of the CF in 3C. If a PPAR&#x003b4; agonist is required for efficient RXR heterodimerisation then the addition of CF would render the PPAR&#x003b4; LBD dominant negative on PPAR&#x003b3;1 signalling. Indeed, we found that the PPAR&#x003b4; LBD could repress the PPAR&#x003b3;1 signalling in the presence of a PPAR&#x003b4; agonist (<xref ref-type="fig" rid="pone-0007046-g003">Figures 3D</xref>, P&#x0003c;0.001).</p><p>Given the known effects of agonist binding to a PPAR one could speculate whether the dominant negative effect of the PPAR&#x003b4; LBD is due to RXR or transcriptional co-activator squelching. To address this question we co-expressed RXR&#x003b1; and the transcriptional co-activator, steroid receptor co-activator 1a (SRC1a), with PPAR&#x003b4; and &#x003b3;1 with and without the PPAR&#x003b4; LBD. PPAR&#x003b4; signalling was found to be repressed by co-expression of the PPAR&#x003b4; LBD (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4A and B</xref>, P&#x0003c;0.001 and P&#x0003c;0.05, respectively). This dominant negative effect was abolished by co-expression of RXR&#x003b1; (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4A</xref>, P&#x0003e;0.05). Co-expression of SRC1a with PPAR&#x003b4; increased the agonist dependent inducibility of reporter activity but didn't abolish the effects of PPAR&#x003b4; LBD dependent repression (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4B</xref>).</p><fig id="pone-0007046-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007046.g004</object-id><label>Figure 4</label><caption><title>The effect of co-expression of RXR&#x003b1; and SRC1a on PPAR&#x003b4; LBD mediated repression of PPAR&#x003b4; (A and B) and PPAR&#x003b3;1 (C and D) signalling, respectively.</title><p>COS-1 cells were transfected with: (A and B) 500 ng pJ3Nuc and the following plasmids: 500 ng pCLDN or pCLDN-&#x003b4;LBD and pCLDN or (A) pSG-mRXR&#x003b1; or (B) pSG5-SRC1a and for (C and D) 50 ng pCLDN-hPPAR&#x003b3;1 and the following plasmids: 500 ng pCLDN or pCLDN-&#x003b4;LBD and 500 ng pCLDN or (C) pSG-mRXR&#x003b1; or (D) pSG5-SRC1a.</p></caption><graphic xlink:href="pone.0007046.g004"/></fig><p>We then proceeded to study the effect of RXR&#x003b1; and SRC1a co-expression on the effect of the PPAR&#x003b4; LBD on PPAR&#x003b3;1 signalling. In this experimental setup the PPAR&#x003b4; LBD showed dominant negative behaviour in the absence of CF (<xref ref-type="fig" rid="pone-0007046-g004">Figures 4C and D</xref>, P&#x0003c;0.001 and P&#x0003c;0.05, respectively). The dominant negative effect of the PPAR&#x003b4; LBD was somewhat enhanced by the PPAR&#x003b4; agonist (<xref ref-type="fig" rid="pone-0007046-g004">Figures 4C and D</xref>). The effect of co-expression of RXR&#x003b1; was similar to that of the PPAR&#x003b4; experiment with overall activity somewhat increased but with lower levels of PPAR&#x003b3; agonist dependent induction and in abolishing the dominant negative effect of the PPAR&#x003b4; LBD (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4C</xref>). Co-expression of SRC1a increased the level of activity of PPAR&#x003b3;1 without having a much of an effect on the level of induction (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>). The PPAR&#x003b4; LBD repressed PPAR&#x003b3;1 signalling (P&#x0003c;0.05) with additional repression seen in the presence of CF (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>). As was the case for PPAR&#x003b4;, the addition of SRC1a increased the overall levels of signalling (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>). Also similarly with the SRC1a co-expression experiment with PPAR&#x003b4; the addition of SRC1a did not abolish the PPAR&#x003b4; LBD mediated repression. Instead, the level of PPAR&#x003b4; LBD mediated repression became more pronounced (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>, P&#x0003c;0.001). Furthermore, the PPAR&#x003b4; agonist enhanced repression was more marked (<xref ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>, P&#x0003c;0.05). Since the addition of RXR&#x003b1; seems to relieve the PPAR&#x003b4; LBD mediated repression of PPAR&#x003b4; and PPAR&#x003b3;1 signalling whereas the addition of SRC1a still allows the PPAR&#x003b4; LBD mediated repression we conclude that RXR sequestration is likely to be the main mechanism behind the phenomenon. We thus speculate that ligand dependent RXR competition could occur <italic>in vivo</italic> between at least PPAR&#x003b4; and PPAR&#x003b3; and quite possible between all three PPAR isoforms.</p></sec><sec id="s2d"><title>Concluding remarks</title><p>The major conclusion we draw from this study is that care must be taken when interpreting results obtained from all genetic models of PPAR&#x003b4; action. The genetic ablation of PPAR&#x003b4; will remove both the ability to activate PPAR&#x003b4;, but also the intrinsic role that PPAR&#x003b4; has in the tempering of PPAR&#x003b1; and PPAR&#x003b3; signalling. Therefore it is prudent to use a wide range of both gain and loss of function experiments in order to fully understand the function of PPAR&#x003b4; and its relationship to PPAR&#x003b1; and PPAR&#x003b3; signalling. This is most likely to be true for other nuclear receptors forming heterodimers with RXRs as well.</p><p>Our study also might suggest a novel paradigm for the design of different functional classes of type II nuclear receptor antagonist drugs. One could envisage two sets of nuclear receptor antagonists with very different biological actions (simplistically stating the two extremes of antagonist behaviour); one that displaces the PPAR/RXR complex from the PPRE and one that simultaneously increases DNA binding and transcriptional co-repressor recruitment.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title>Cloning and plasmids</title><p>General DNA techniques were performed according to <xref ref-type="bibr" rid="pone.0007046-Sambrook1">&#x0005b;27&#x0005d;</xref>. DNA sequencing was done by the DNA Analysis Facility, Human Genetics Unit, at Ninewells Hospital, Dundee. <italic>Escherichia coli</italic> XL1 Blue was transformed according to the manufacturer's instructions (Stratagene).</p><p>The expression plasmids pCLDN-hPPAR&#x003b4; (pMGD60), pCLDN-hPPAR&#x003b4;&#x00394;AF2, pCLDN-hPPAR&#x003b3;1, pJ3NUC, pCMVg-RXR, pSG-mRXR&#x003b1; and pSG5-SRC1a as well as the PPRE reporter plasmid pLFABPluc have been described previously <xref ref-type="bibr" rid="pone.0007046-TargettAdams1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Adamson1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Schmidt1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Solomin1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Allenby1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Kalkhoven1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007046-Vosper1">&#x0005b;33&#x0005d;</xref>. The internal transfection control plasmid pSV&#x003b2;-galactosidase is from Promega. The part of human <italic>PPAR&#x003b4;</italic> encoding the LBD (from codon A142, including an added translational start codon, in bold) was amplified with primers PRMG4 (<named-content content-type="gene">5&#x02032;-CGG<underline>GGTACC</underline><bold>ATG</bold>GCTATCCGTTTTGGTCGGATG-3&#x02032;</named-content>) and PRMG5 (<named-content content-type="gene">5&#x02032;-CGG<underline>GGTACC</underline>TTAGTACATGTCCTTGTAGATCTCC-3&#x02032;</named-content>) (<italic>Kpn</italic>I-sites underlined). The <italic>Kpn</italic>I cleaved PCR product was cloned into pCLDN <xref ref-type="bibr" rid="pone.0007046-Aiyar1">&#x0005b;34&#x0005d;</xref>, creating pCLDN-&#x003b4;LBD (confirmed by sequencing). A GAL4-fusion luciferase reporter plasmid (p4&#x000d7;UAS-TK-luc) was constructed by cloning the <italic>Sal</italic>I-<italic>Xho</italic>I fragment of pLacZr <xref ref-type="bibr" rid="pone.0007046-Solomin1">&#x0005b;30&#x0005d;</xref> (containing the 4&#x000d7;UAS-TK, Upstream Activating Sequence) module in pGL3basic (Promega) cleaved with <italic>Xho</italic>I.</p></sec><sec id="s3b"><title>Growth of cells and transient transfections</title><p>COS-1 and T47D cells (Cancer Research U. K. cell resources unit) were grown in a 5&#x00025; CO<sub>2</sub> atmosphere at 37&#x000b0;C in high glucose DMEM supplemented with 10&#x00025; foetal bovine serum and 50 U/ml penicillin G and 50 &#x000b5;g/ml streptomycin (Gibco) and 2 mM L-glutamine for COS-1 and T47D cells, respectively. For transfections the T47D cells were grown in RPMI 1640 (phenol red-free) containing 5&#x00025; dextran-charcoal stripped foetal bovine serum. Transient transfections of COS-1 cells and T47D cells were performed in six-well plates using DEAE-dextran according to Cullen <xref ref-type="bibr" rid="pone.0007046-Cullen1">&#x0005b;35&#x0005d;</xref> and Lipofectamine 2000 (Invitrogen), respectively. 24 hours post transfection, medium containing 50 nM compound F, CF, <xref ref-type="bibr" rid="pone.0007046-Vosper1">&#x0005b;33&#x0005d;</xref> for PPAR&#x003b4; activation and/or 500 nM rosiglitazone, BRL, <xref ref-type="bibr" rid="pone.0007046-Lehmann1">&#x0005b;36&#x0005d;</xref> for PPAR&#x003b3;1 activation in a final concentration of 0.1&#x00025; dimethyl sulfoxide (DMSO) or DMSO alone was added. 48 hours post transfection cell lysates were generated using Promega's reporter lysis buffer.</p><p>For all transfections 500 ng luciferase reporter (pLFABPluc or p4&#x000d7;UAS-TK-luc) and 50 ng pSV&#x003b2;-galactosidase were used per well in six-well plates. Luciferase activity was assayed with the Promega luciferase assay substrate and &#x003b2;-galactosidase activity according to Sambrook et al. using o-nitrophenyl-&#x003b2;-D-galactopyranoside <xref ref-type="bibr" rid="pone.0007046-Sambrook1">&#x0005b;27&#x0005d;</xref> or using the chemiluminescent &#x003b2;-gal reporter gene assay kit from Roche.</p></sec><sec id="s3c"><title>Statistical analysis</title><p>Relative reporter gene expression is stated as the luciferase activity normalized against the corresponding &#x003b2;-galactosidase activity. These values have in turn been normalised against the mean of the normalized luciferase activities of the leftmost bars in each graph. Each experiment was repeated three times and the bars in the graphs represent the means and the error bars represent the standard error of the mean. One-way ANOVA was performed on the data from each experiment and the Newman-Keuls test was employed for calculating statistical significance using GraphPad Prism 3 software.</p></sec></sec></body><back><ref-list><title>References</title><ref id="pone.0007046-Desvergne1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><year>1999</year><article-title>Peroxisome proliferator-activated receptors: nuclear control of metabolism.</article-title><source>Endocr Rev</source><volume>20</volume><fpage>649</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">10529898</pub-id></mixed-citation></ref><ref id="pone.0007046-Staels1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name></person-group><year>2005</year><article-title>Therapeutic roles of peroxisome proliferator-activated receptor agonists.</article-title><source>Diabetes</source><volume>54</volume><fpage>2460</fpage><lpage>2470</lpage><pub-id pub-id-type="pmid">16046315</pub-id></mixed-citation></ref><ref id="pone.0007046-Willson1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Sternbach</surname><given-names>DD</given-names></name><name><surname>Henke</surname><given-names>BR</given-names></name></person-group><year>2000</year><article-title>The PPARs: from orphan receptors to drug discovery.</article-title><source>J Med Chem</source><volume>43</volume><fpage>527</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">10691680</pub-id></mixed-citation></ref><ref id="pone.0007046-Tachibana1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname><given-names>K</given-names></name><name><surname>Yamasaki</surname><given-names>D</given-names></name><name><surname>Ishimoto</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name></person-group><year>2008</year><article-title>The Role of PPARs in Cancer.</article-title><source>PPAR Res</source><volume>2008</volume><fpage>102737</fpage><pub-id pub-id-type="pmid">18584037</pub-id></mixed-citation></ref><ref id="pone.0007046-Tontonoz1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><year>2008</year><article-title>Fat and beyond: the diverse biology of PPAR&#x003b3;.</article-title><source>Annu Rev Biochem</source><volume>77</volume><fpage>289</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">18518822</pub-id></mixed-citation></ref><ref id="pone.0007046-Abbott1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>BD</given-names></name></person-group><year>2008</year><article-title>Review of the expression of peroxisome proliferators-activated receptors alpha (PPAR&#x003b1;), beta (PPAR&#x003b2;), and gamma (PPAR&#x003b3;) in rodent and human development.</article-title><source>Reprod Toxicol</source></mixed-citation></ref><ref id="pone.0007046-Desvergne2"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Michalik</surname><given-names>L</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><year>2006</year><article-title>Transcriptional regulation of metabolism.</article-title><source>Physiol Rev</source><volume>86</volume><fpage>465</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">16601267</pub-id></mixed-citation></ref><ref id="pone.0007046-Seedorf1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seedorf</surname><given-names>U</given-names></name><name><surname>Aberle</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Emerging roles of PPAR&#x003b4; in metabolism.</article-title><source>Biochim Biophys Acta</source><volume>1771</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">17588807</pub-id></mixed-citation></ref><ref id="pone.0007046-Takahashi1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>New therapeutic target for metabolic syndrome: PPAR&#x003b4;.</article-title><source>Endocr J</source><volume>54</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">17409576</pub-id></mixed-citation></ref><ref id="pone.0007046-Riserus1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riserus</surname><given-names>U</given-names></name><name><surname>Sprecher</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Hirschberg</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>Activation of peroxisome proliferator-activated receptor (PPAR)&#x003b4; promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.</article-title><source>Diabetes</source><volume>57</volume><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">18024853</pub-id></mixed-citation></ref><ref id="pone.0007046-Sprecher1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprecher</surname><given-names>DL</given-names></name><name><surname>Massien</surname><given-names>C</given-names></name><name><surname>Pearce</surname><given-names>G</given-names></name><name><surname>Billin</surname><given-names>AN</given-names></name><name><surname>Perlstein</surname><given-names>I</given-names></name><etal/></person-group><year>2007</year><article-title>Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor &#x003b4; agonist.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>27</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">17110604</pub-id></mixed-citation></ref><ref id="pone.0007046-Krogsdam1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogsdam</surname><given-names>AM</given-names></name><name><surname>Nielsen</surname><given-names>CA</given-names></name><name><surname>Neve</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>D</given-names></name><name><surname>Helledie</surname><given-names>T</given-names></name><etal/></person-group><year>2002</year><article-title>Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor &#x003b4;-mediated transactivation.</article-title><source>Biochem J</source><volume>363</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">11903058</pub-id></mixed-citation></ref><ref id="pone.0007046-Shi1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Hon</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><year>2002</year><article-title>The peroxisome proliferator-activated receptor &#x003b4;, an integrator of transcriptional repression and nuclear receptor signaling.</article-title><source>Proc Natl Acad Sci U S A</source><volume>99</volume><fpage>2613</fpage><lpage>2618</lpage><pub-id pub-id-type="pmid">11867749</pub-id></mixed-citation></ref><ref id="pone.0007046-Barroso1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Crowley</surname><given-names>VE</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name><etal/></person-group><year>1999</year><article-title>Dominant negative mutations in human PPAR&#x003b3; associated with severe insulin resistance, diabetes mellitus and hypertension.</article-title><source>Nature</source><volume>402</volume><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10622252</pub-id></mixed-citation></ref><ref id="pone.0007046-Hatae1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatae</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>C</given-names></name><name><surname>Shimonishi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>T</given-names></name></person-group><year>2001</year><article-title>Prostacyclin-dependent apoptosis mediated by PPAR&#x003b4;.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>46260</fpage><lpage>46267</lpage><pub-id pub-id-type="pmid">11551955</pub-id></mixed-citation></ref><ref id="pone.0007046-Michalik1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalik</surname><given-names>L</given-names></name><name><surname>Feige</surname><given-names>JN</given-names></name><name><surname>Gelman</surname><given-names>L</given-names></name><name><surname>Pedrazzini</surname><given-names>T</given-names></name><name><surname>Keller</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.</article-title><source>Mol Endocrinol</source><volume>19</volume><fpage>2335</fpage><lpage>2348</lpage><pub-id pub-id-type="pmid">15890673</pub-id></mixed-citation></ref><ref id="pone.0007046-TargettAdams1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targett-Adams</surname><given-names>P</given-names></name><name><surname>McElwee</surname><given-names>MJ</given-names></name><name><surname>Ehrenborg</surname><given-names>E</given-names></name><name><surname>Gustafsson</surname><given-names>MC</given-names></name><name><surname>Palmer</surname><given-names>CN</given-names></name><etal/></person-group><year>2005</year><article-title>A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein.</article-title><source>Biochim Biophys Acta</source><volume>1728</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">15777674</pub-id></mixed-citation></ref><ref id="pone.0007046-Forman1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>BM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><year>1997</year><article-title>Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors &#x003b1; and &#x003b4;.</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><fpage>4312</fpage><lpage>4317</lpage><pub-id pub-id-type="pmid">9113986</pub-id></mixed-citation></ref><ref id="pone.0007046-He1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year>1999</year><article-title>PPAR&#x003b4; is an APC-regulated target of nonsteroidal anti-inflammatory drugs.</article-title><source>Cell</source><volume>99</volume><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">10555149</pub-id></mixed-citation></ref><ref id="pone.0007046-Shearer1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>BG</given-names></name><name><surname>Steger</surname><given-names>DJ</given-names></name><name><surname>Way</surname><given-names>JM</given-names></name><name><surname>Stanley</surname><given-names>TB</given-names></name><name><surname>Lobe</surname><given-names>DC</given-names></name><etal/></person-group><year>2008</year><article-title>Identification and characterization of a selective peroxisome proliferator-activated receptor &#x003b2;/&#x003b4; (NR1C2) antagonist.</article-title><source>Mol Endocrinol</source><volume>22</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">17975020</pub-id></mixed-citation></ref><ref id="pone.0007046-Ide1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Yahagi</surname><given-names>N</given-names></name><name><surname>Amemiya-Kudo</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Cross-talk between peroxisome proliferator-activated receptor (PPAR) &#x003b1; and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.</article-title><source>Mol Endocrinol</source><volume>17</volume><fpage>1255</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">12730332</pub-id></mixed-citation></ref><ref id="pone.0007046-Yoshikawa1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Yahagi</surname><given-names>N</given-names></name><name><surname>Amemiya-Kudo</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Cross-talk between peroxisome proliferator-activated receptor (PPAR) &#x003b1; and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.</article-title><source>Mol Endocrinol</source><volume>17</volume><fpage>1240</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">12730331</pub-id></mixed-citation></ref><ref id="pone.0007046-Matsusue1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsusue</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>A</given-names></name><name><surname>Yamano</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year>2006</year><article-title>Ligand-activated PPAR&#x003b2; efficiently represses the induction of LXR-dependent promoter activity through competition with RXR.</article-title><source>Mol Cell Endocrinol</source><volume>256</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16806672</pub-id></mixed-citation></ref><ref id="pone.0007046-Chu1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>R</given-names></name><name><surname>Madison</surname><given-names>LD</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Kopp</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name><etal/></person-group><year>1995</year><article-title>Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding &#x003b2;-oxidation enzymes: cross talk between peroxisome proliferator and T3 signaling pathways.</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><fpage>11593</fpage><lpage>11597</lpage><pub-id pub-id-type="pmid">8524810</pub-id></mixed-citation></ref><ref id="pone.0007046-Ying1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>O</given-names></name><name><surname>Furuya</surname><given-names>F</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group><year>2007</year><article-title>Impaired adipogenesis caused by a mutated thyroid hormone &#x003b1;1 receptor.</article-title><source>Mol Cell Biol</source><volume>27</volume><fpage>2359</fpage><lpage>2371</lpage><pub-id pub-id-type="pmid">17220280</pub-id></mixed-citation></ref><ref id="pone.0007046-Araki1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>O</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Furuya</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group><year>2005</year><article-title>Thyroid hormone receptor &#x003b2; mutants: Dominant negative regulators of peroxisome proliferator-activated receptor &#x003b3; action.</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>16251</fpage><lpage>16256</lpage><pub-id pub-id-type="pmid">16260719</pub-id></mixed-citation></ref><ref id="pone.0007046-Sambrook1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambrook</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>DW</given-names></name></person-group><year>2001</year><article-title>Molecular Cloning: A laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.</article-title></mixed-citation></ref><ref id="pone.0007046-Adamson1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamson</surname><given-names>DJ</given-names></name><name><surname>Frew</surname><given-names>D</given-names></name><name><surname>Tatoud</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Palmer</surname><given-names>CN</given-names></name></person-group><year>2002</year><article-title>Diclofenac antagonizes peroxisome proliferator-activated receptor-&#x003b3; signaling.</article-title><source>Mol Pharmacol</source><volume>61</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11752200</pub-id></mixed-citation></ref><ref id="pone.0007046-Schmidt1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Endo</surname><given-names>N</given-names></name><name><surname>Rutledge</surname><given-names>SJ</given-names></name><name><surname>Vogel</surname><given-names>R</given-names></name><name><surname>Shinar</surname><given-names>D</given-names></name><etal/></person-group><year>1992</year><article-title>Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.</article-title><source>Mol Endocrinol</source><volume>6</volume><fpage>1634</fpage><lpage>1641</lpage><pub-id pub-id-type="pmid">1333051</pub-id></mixed-citation></ref><ref id="pone.0007046-Solomin1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomin</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>CB</given-names></name><name><surname>Zetterstrom</surname><given-names>RH</given-names></name><name><surname>Bissonnette</surname><given-names>RP</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name><etal/></person-group><year>1998</year><article-title>Retinoid-X receptor signalling in the developing spinal cord.</article-title><source>Nature</source><volume>395</volume><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">9759732</pub-id></mixed-citation></ref><ref id="pone.0007046-Allenby1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allenby</surname><given-names>G</given-names></name><name><surname>Bocquel</surname><given-names>MT</given-names></name><name><surname>Saunders</surname><given-names>M</given-names></name><name><surname>Kazmer</surname><given-names>S</given-names></name><name><surname>Speck</surname><given-names>J</given-names></name><etal/></person-group><year>1993</year><article-title>Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">8380496</pub-id></mixed-citation></ref><ref id="pone.0007046-Kalkhoven1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkhoven</surname><given-names>E</given-names></name><name><surname>Valentine</surname><given-names>JE</given-names></name><name><surname>Heery</surname><given-names>DM</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name></person-group><year>1998</year><article-title>Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor.</article-title><source>Embo J</source><volume>17</volume><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">9427757</pub-id></mixed-citation></ref><ref id="pone.0007046-Vosper1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vosper</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>TL</given-names></name><name><surname>Khoudoli</surname><given-names>GA</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><etal/></person-group><year>2001</year><article-title>The peroxisome proliferator-activated receptor &#x003b4; promotes lipid accumulation in human macrophages.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>44258</fpage><lpage>44265</lpage><pub-id pub-id-type="pmid">11557774</pub-id></mixed-citation></ref><ref id="pone.0007046-Aiyar1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiyar</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>HL</given-names></name><name><surname>Nambi</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>RM</given-names></name><etal/></person-group><year>1994</year><article-title>Human AT1 receptor is a single copy gene: characterization in a stable cell line.</article-title><source>Mol Cell Biochem</source><volume>131</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">8047068</pub-id></mixed-citation></ref><ref id="pone.0007046-Cullen1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><year>1987</year><article-title>Use of eukaryotic expression technology in the functional analysis of cloned genes.</article-title><source>Methods Enzymol</source><volume>152</volume><fpage>684</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">3657593</pub-id></mixed-citation></ref><ref id="pone.0007046-Lehmann1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>Moore</surname><given-names>LB</given-names></name><name><surname>Smith-Oliver</surname><given-names>TA</given-names></name><name><surname>Wilkison</surname><given-names>WO</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><etal/></person-group><year>1995</year><article-title>An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;).</article-title><source>J Biol Chem</source><volume>270</volume><fpage>12953</fpage><lpage>12956</lpage><pub-id pub-id-type="pmid">7768881</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was financed by the Medical Research Council Career Development Award G0000119 (<ext-link ext-link-type="uri" xlink:href="http://www.mrc.ac.uk">www.mrc.ac.uk</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>